Nevertheless, GLP-1 RAs are not recommended in subjects at high risk of developing MTC, such as a known personal or family history of MTC and/or multiple endocrine neoplasia type 2A and 2B [33,60]. Here, GLP1R is linked to medullary thyroid gland carcinoma.